A Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study of BPN14770 in Adult Males With Fragile X Syndrome
Phase of Trial: Phase II
Latest Information Update: 16 Jul 2018
At a glance
- Drugs BPN 14770 (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions
- Sponsors Tetra Discovery Partners
- 10 Jul 2018 According to a Tetra Discovery Partners media release, this trial is being conducted with financial support from the FRAXA Research Foundation.
- 27 Jun 2018 Status changed from not yet recruiting to recruiting.
- 14 Jun 2018 Status changed from planning to not yet recruiting.